S D Pharmaceuticals Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: S D Pharmaceuticals Pharmaceutical Export Portfolio Dataset — 6 Products, $753.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

S D Pharmaceuticals — Pharmaceutical Exporter Profile (2026) | 6 Products, $753.6K Trade | TransData Nexus

Product Portfolio — Top 6 by Export Value

S D Pharmaceuticals exports 6 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Bromhexine	Respiratory & OTC	$225.0K	17	1.4%	14
2	Temozolomide	Advanced Oncology	$156.4K	4	0.7%	9
3	Amiodarone	Cardiovascular	$150.0K	3	0.2%	14
4	Raltegravir	Antiviral & HIV Medications	$150.0K	3	2.3%	3
5	Pyrantel	Antimalarial & Antiparasitic	$39.3K	4	1.2%	10
6	Atazanavir	Antiviral & HIV Medications	$32.9K	4	0.0%	7

S D Pharmaceuticals exports 6 pharmaceutical products across 5 therapeutic categories with a total export value of $753.6K. The top category is Respiratory & OTC (29.9% of portfolio), followed by Antiviral & HIV Medications (24.3%), indicating a concentrated portfolio with the top 5 products accounting for 95.6% of total export value.

S D Pharmaceuticals — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

S D Pharmaceuticals is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 1991, the company is headquartered in Muzaffarnagar, Uttar Pradesh, India. It is registered under the Corporate Identification Number (CIN) U24231UP1991PTC012999. The authorized capital is ₹1.5 million, with a paid-up capital of ₹1.18 million. The company's last Annual General Meeting (AGM) was held on 30 September 2011, and the balance sheet was filed on 31 March 2011.

2Manufacturing Facilities

S D Pharmaceuticals operates manufacturing facilities in Muzaffarnagar, Uttar Pradesh, India. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and certifications are not publicly available.

3Key Leadership

The company's leadership includes Managing Director Rajender Kumar, who has been in this role since 16 December 1992, and Director Partibha Goyal, appointed on 1 April 2002. Both have been associated with the company for several decades, contributing to its strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does S D Pharmaceuticals Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

S D Pharmaceuticals' export data indicates shipments to various countries, including Venezuela, Iran, the United Arab Emirates, and others. However, specific regulatory approvals or market access statuses in the US, EU, UK, Australia, and Japan are not publicly disclosed. The company's focus appears to be on markets in Latin America, the Middle East, and Africa.

2Emerging Markets

The company's export data highlights significant shipments to countries in Latin America, such as Venezuela and Nicaragua, as well as to the Middle East, including Iran and Iraq. These regions are emerging markets for S D Pharmaceuticals, indicating a strategic focus on expanding its presence in these areas.

3Geographic Strategy

S D Pharmaceuticals demonstrates a concentrated export strategy, with a significant portion of its shipments directed towards Latin American and Middle Eastern countries. This focus suggests a deliberate approach to penetrate and establish a foothold in these emerging markets. The company's portfolio concentration, with the top five products accounting for 95.6% of total export value, indicates a strategic emphasis on a select range of products.

S D Pharmaceuticals — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding S D Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not indicate shipments to the United States, suggesting limited or no market presence in the U.S.

2WHO & EU GMP

There is no publicly available information regarding S D Pharmaceuticals' compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's export data does not provide insights into these certifications.

3CDSCO & Indian Regulatory

S D Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data does not provide information on these regulatory aspects.

S D Pharmaceuticals — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

S D Pharmaceuticals operates in a competitive landscape with numerous pharmaceutical exporters from India. While specific competitors in overlapping categories are not identified, the company's focus on select therapeutic categories and emerging markets positions it uniquely. The portfolio concentration, with the top five products accounting for 95.6% of total export value, suggests a strategic emphasis on a narrow product range, which may influence its competitive positioning.

2Key Differentiators

S D Pharmaceuticals' key differentiators include its strategic focus on emerging markets in Latin America and the Middle East, as evidenced by its export data. The company's concentrated product portfolio, with the top five products accounting for 95.6% of total export value, indicates a specialized approach to product offerings. However, the lack of publicly available information on regulatory certifications and approvals may impact its competitive advantages.

3Strategic Position

S D Pharmaceuticals appears to be strategically positioned as a specialized exporter focusing on select therapeutic categories and emerging markets. The company's export data indicates a deliberate approach to penetrate and establish a presence in regions such as Latin America and the Middle East. The concentrated product portfolio suggests a focus on specific products, which may influence its strategic direction in the global pharmaceutical market.

Buyer Due Diligence Brief — Evaluating S D Pharmaceuticals as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

S D Pharmaceuticals has demonstrated a consistent export track record, with a total export value of $754,000 USD across 35 shipments from 2022 to 2026. The company's export data indicates shipments to 153 buyers, primarily in Latin America and the Middle East, suggesting a reliable supply chain and customer base. However, the lack of publicly available information on regulatory certifications and approvals may require further due diligence for potential partners.

2Certifications to Verify

Importers should verify the following certifications when considering S D Pharmaceuticals as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify compliance with World Health Organization Good Manufacturing Practice standards to ensure product quality and safety.

Frequently Asked Questions — S D Pharmaceuticals

How many pharmaceutical products does S D Pharmaceuticals export from India?

S D Pharmaceuticals exports 6 pharmaceutical products across 5 therapeutic categories. The top exports are Bromhexine ($225.0K), Temozolomide ($156.4K), Amiodarone ($150.0K), Raltegravir ($150.0K), Pyrantel ($39.3K). Total export value is $753.6K.

What is S D Pharmaceuticals's total pharmaceutical export value?

S D Pharmaceuticals's total pharmaceutical export value is $753.6K, based on 35 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does S D Pharmaceuticals cover?

S D Pharmaceuticals exports across 5 therapeutic categories. The largest are Respiratory & OTC (29.9%, 1 products), Antiviral & HIV Medications (24.3%, 2 products), Advanced Oncology (20.7%, 1 products).

Get Full S D Pharmaceuticals Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

S D Pharmaceuticals

S D Pharmaceuticals — Export Portfolio & Destination Treemap

Who is S D Pharmaceuticals? — Company Overview & Market Position

What Does S D Pharmaceuticals Export? — Product Portfolio Analysis

Top Products by Export Value

S D Pharmaceuticals Therapeutic Categories — 5 Specializations